Anika Therapeutics, Inc.

ANIK

US0352551081

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
25.57 ^USD	-0.04%		-1.04%	+12.84%

Mar. 14	Barrington Ups Price Target on Anika Therapeutics to $37 From $29, Keeps Outperform Rating	MT
Mar. 13	Transcript : Anika Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024

Anika Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2024

March 13, 2024 at 04:05 pm EDT

Anika Therapeutics, Inc. provided earnings guidance for the fiscal year 2024. The company expects revenue for fiscal year 2024 of $168 million to $173 million, representing growth of 1% to 4% compared to 2023.

Latest news about Anika Therapeutics, Inc.

Barrington Ups Price Target on Anika Therapeutics to $37 From $29, Keeps Outperform Rating	Mar. 14	MT
Transcript : Anika Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024	Mar. 13
Anika Therapeutics Swings to Q4 Earnings As Revenue Rises; to Cut 9% Workforce	Mar. 13	MT
Anika Therapeutics Guides For FY 2024 Revenue of $168-$173 Million, vs CIQ Analyst Consensus of $179 Million	Mar. 13	MT
Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q4 EPS $0.05, vs. Street Est of $-0.23	Mar. 13	MT
Earnings Flash (ANIK) ANIKA THERAPEUTICS Posts Q4 Revenue $43M, vs. Street Est of $41.4M	Mar. 13	MT
Anika Therapeutics, Inc. Provides Earnings Guidance for the Fiscal Year 2024	Mar. 13	CI
Anika Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
Anika Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Activist investor Caligan discloses 9.7% stake in Anika, nominates two director candidates	Mar. 07	RE
Caligan Partners LP Issues Notice of Nominations to Anika Therapeutics, Inc	Mar. 06	CI
Anika Therapeutics, Inc. Announces Board Changes	Feb. 26	CI
Barrington Ups Price Target on Anika Therapeutics to $29 From $28, Reiterates Outperform Rating	Jan. 04	MT
Anika Therapeutics Says Surgeries Using Integrity Implant System Successful	Nov. 28	MT
Anika Therapeutics, Inc. Announces First Surgeries Performed Using the Integrity Implant System	Nov. 28	CI
Barrington Ups PT on Anika Therapeutics to $28 From $24, Expecting JPR Business to Produce 'Double-digit, Top-line Growth', Maintains Outperform Rating	Nov. 03	MT
Tranche Update on Anika Therapeutics, Inc.'s Equity Buyback Plan announced on April 13, 2023.	Nov. 03	CI
Transcript : Anika Therapeutics, Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Earnings Flash (ANIK) ANIKA THERAPEUTICS Posts Q3 EPS $0.00, vs. Street Est of $-0.35	Nov. 02	MT
Earnings Flash (ANIK) ANIKA THERAPEUTICS Reports Q3 Revenue $41.5M, vs. Street Est of $38.3M	Nov. 02	MT
Anika Therapeutics, Inc. Revises Revenue Guidance for the Fiscal Year 2023	Nov. 02	CI
Anika Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Anika Therapeutics, Inc. Announces the Full Market Release of the Revomotion Reverse Shoulder Arthroplasty System	23-09-19	CI
Anika Therapeutics, Inc.(NasdaqGS:ANIK) dropped from S&P Biotechnology Select Industry Index	23-09-18	CI
Anika Therapeutics, Inc.(NasdaqGS:ANIK) dropped from S&P 600	23-09-18	CI

Chart Anika Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Anika Therapeutics, Inc. is a joint preservation company focused on developing, manufacturing, and commercializing products based on hyaluronic acid (HA) technology platform. The OA Pain Management product family consists of Monovisc and Orthovisc that provides pain relief from osteoarthritis conditions and Cingal consisting of its cross-linked HA material combined with a fast-acting steroid. Its Joint Preservation and Restoration product family consists of its portfolio of orthopedic regenerative solutions products: Integrity, Tactoset, and Hyalofast; its line of sports medicine solutions repairs and reconstructs damaged ligaments and tendons, and its Arthrosurface portfolio of bone preserving joint technologies, including partial joint replacement, joint resurfacing, and minimally invasive and bone sparing implants. Its Non-Orthopedic product family provides orthopedic applications, including adhesion barrier product, advanced wound care products, and ear, nose and throat products.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Anika Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

25.57 USD

Average target price

30.33 USD

Spread / Average Target

+18.63%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
ANIKA THERAPEUTICS, INC.	+12.84%	375M
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
BIOMARIN PHARMACEUTICAL INC.	-16.09%	15.35B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
INCYTE CORPORATION	-17.69%	11.6B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B

Biopharmaceuticals